Previous 10 | Next 10 |
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
2024-03-10 12:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
REYKJAVIK, Iceland, March 05, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the full year 2023, after U.S. markets...
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chi...
2024-02-26 05:04:34 ET Alvotech ( NASDAQ: ALVO ) and partner Teva Pharmaceuticals ( NYSE: TEVA ) announced Friday the U.S. Food and Drug Administration (FDA) approval for their arthritis injection, Simlandi (adalimumab-ryvk).... Read the full article on Seeking Alp...
REYKJAVIK, Iceland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “Investors”) for ...
SIMLANDI is t he first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S . SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market...
2024-02-15 10:10:42 ET More on Alvotech Alvotech: Biosimilars Portfolio Opportunity Is High Risk Alvotech (ALVO) Q3 2023 Earnings Call Transcript Evolus, Alvotech gain as Barclays raises to Ovrweight Alvotech stock jumps 15% on Stelara, Humira biosimilars upd...
REYKJAVIK, Iceland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, Ca...
News, Short Squeeze, Breakout and More Instantly...
Alvotech Company Name:
ALVO Stock Symbol:
NASDAQ Market:
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufa...
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference in New York on June 5-6, ...
2024-05-24 07:00:07 ET Balaji Prasad from Barclays issued a price target of $22.00 for ALVO on 2024-05-24 05:26:00. The adjusted price target was set to $22.00. At the time of the announcement, ALVO was trading at $13.58. The overall price target consensus is at $15.00 w...